Navigation Links
Genomic Health Announces First Quarter 2008 Financial Results and Business Progress
Date:5/6/2008

ned an expanded coverage policy from WellPoint, Inc., a leading

health benefits provider, to include the majority of women diagnosed

with node-negative, estrogen receptor-positive breast cancer.

International

-- Established exclusive marketing agreement with GeneKor to distribute

Oncotype DX in Greece.

-- Expanded partnership with Teva Pharmaceutical Industries Ltd. to

include distribution of Oncotype DX in Turkey.

Pipeline

-- Studies presented at the American Society of Clinical Oncology's

Gastrointestinal Cancers Symposium in January identified genes that

could help predict the likelihood of recurrence and chemotherapy

benefit for early-stage (stage II and III) colon cancer.

-- Based on multiple clinical studies and analysis, reached a key

milestone with the finalization of an 18-gene panel for our Oncotype DX

colon cancer assay, which is now undergoing analytical validation. The

company anticipates beginning a clinical validation study of the assay

in the second half of 2008.

-- Announced plans to evaluate the use of the Oncotype DX 21-gene breast

cancer panel, and also seek to identify other genes that may be used

for treatment planning in women with ductal carcinoma in situ, or DCIS,

which affects approximately 60,000 women per year in the United States.

-- Under our collaboration with Pfizer, we received our first payments for

the initiation of research to develop a genomic test to estimate the

risk of recurrence following surgery for patients with stage I-III

renal carcinoma, clear cell type.

Conference Call Details

To access the live conference call today, May 6 at 4:30 p.m. Eastern Time via phone, please dial (877) 356-8064 from the United States and Canada or (706) 758-4314 internationally. The conference ID is 45418205. Please dial in appr
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
3. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
4. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
7. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
8. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Alba Therapeutics Corporation today,announced that its Investigational New ... endogenous insulin production capacity in new-onset,type 1 diabetes ... period,by the U.S. Food and Drug Administration (FDA). ... in 2008 while focusing the majority,of its development ...
... Sept. 5 Thermo Fisher,Scientific Inc. (NYSE: ... has,acquired the instrument sales business of Davis Inotek ... Instruments and excludes its,related calibration services. Davis Instruments ... control instruments, serving customers in a,wide range of ...
... A study in the August 2007,issue of ... GlycoMark,1,5-anhydroglucitol (1,5-AG) blood test to evaluate therapy ... hyperglycemia (elevated,after-meal glucose levels). Controlling after-meal glucose ... and reducing the burden of,cardiovascular complications, the ...
Cached Biology Technology:Alba Therapeutics Announces IND for Beta Cell Preservation in Type 1 Diabetes Using AT-1001 2Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 2Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 3Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 4Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes 2
(Date:7/9/2014)... one of the amphibians with the highest distribution in ... of water where it comes into contact with the ... carried out by the Spaniard Germn Orizaola from the ... these frogs have developed a defensive response to the ... bodies if they co-exist with the crayfish. , Numerous ...
(Date:7/9/2014)... increase the survival rate of naturally aged animals? ... Pharmaceutical Sciences, Southwest University, China performed an animal ... low dose of levothyroxine for 3 consecutive months. ... obvious improvement in cognitive and an increased rat ... mechanism was demonstrated that levothyroxine treatment can increase ...
(Date:7/9/2014)... cancer patients with high levels of vitamin D in their ... shows. , Patients with the highest levels of vitamin ... with the lowest levels, the findings reveal. , The study ... D in bowel cancer patients after their diagnosis which ... from dietary sources with their long term survival prospects. ...
Breaking Biology News(10 mins):Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3
... Mental Health (CAMH) is proud to announce a landmark ... Innovation (CFI) into research that will propel the understanding, ... to the next level of excellence. This ... Research Hospital Fund will allow CAMH to leverage our ...
... new study in the September issue of the Journal ... may have a role in the rising rate of diabetes, ... , DNA is the primary mechanism of inheritance; kids get ... scientists are just starting to understand additional kinds of inheritance ...
... invasion of unwanted species, according to a recent U.S. ... the reef and eliminate all the native coral, dramatically ... This study documents for the first time that a ... reef is unambiguously associated with man-made structures. ...
Cached Biology News:Large-scale investment catapults CAMH's mental illness and addiction research forward 2Shipwrecks on coral reefs harbor unwanted species 2
Recombinant Equine IL-6...
... Checker Kits provide two highly efficient methods ... time-consuming plasmid preparation. By using the large-scale ... need to do is to transfer partial ... the transformation plates into the solutions provided ...
... Butcher (1998). • The major histocompatibility complex ... the immunology area. There is great interest ... in their function as antigen-presenting molecules. Many ... prospect of tackling biochemical and genetic techniques ...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Biology Products: